ARCT 8-K: Material agreement

Arcturus Therapeutics

Filed with the SEC on · accession 0001193805-26-001485

ARCT filed a 8-K (current report) with the SEC on Nov 16, 2026. Arcturus Therapeutics entered into a Securities Purchase Agreement with Meiji Seika Pharma, selling 2,466,395 shares of common stock for $50.0 million at an 80% premium to the 30-day average closing price. The stock moved +5.9% by the first close after the filing.

Summary of the filing

Arcturus Therapeutics entered into a Securities Purchase Agreement with Meiji Seika Pharma, selling 2,466,395 shares of common stock for $50.0 million at an 80% premium to the 30-day average closing price. The parties also entered a license agreement for ARCT-154 technology and a non-binding MOU for an exclusive license to self-amplifying mRNA and LNP technologies for pandemic preparedness in Japan.

Key details

Aggregate purchase price for 2,466,395 shares of common stock$50.0M
Potential refund of 50% of premium if definitive license agreement not entered by May 31, 2027$11.1M
IssuerArcturus Therapeutics Holdings Inc.
Investor and collaboration partnerMeiji Seika Pharma Co., Ltd.

How ARCT stock reacted

Close before

$8.36

Nov 13, 2026

First close after

+5.86%

$8.85

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for ARCT, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ARCT?

Click here

Frequently asked questions

What did ARCT file with the SEC on Nov 16, 2026?

ARCT filed a 8-K (Material agreement). Arcturus Therapeutics entered into a Securities Purchase Agreement with Meiji Seika Pharma, selling 2,466,395 shares of common stock for $50.0 million at an 80% premium to the 30-day average closing price. The parties also entered a license agreement for ARCT-154 technology and a non-binding MOU for an exclusive license to self-amplifying mRNA and LNP technologies for pandemic preparedness in Japan.

What does a material agreement mean for ARCT stock?

A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did ARCT stock react to this filing?

ARCT closed at $8.36 before the filing and $8.85 on Nov 16, 2026 (+5.86%).

Other ARCT SEC filings

Get alerts when ARCT files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days